Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%

TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating more than a 38% increase from its prior forecast.